Literature DB >> 15313935

Pulmonary prostacyclin synthase overexpression chemoprevents tobacco smoke lung carcinogenesis in mice.

Robert L Keith1, York E Miller, Tyler M Hudish, Carlos E Girod, Sylk Sotto-Santiago, Wilbur A Franklin, Raphael A Nemenoff, Thomas H March, S Patrick Nana-Sinkam, Mark W Geraci.   

Abstract

Increased pulmonary production of prostaglandin I2 (prostacyclin) by lung-specific overexpression of prostacyclin synthase decreases lung tumor incidence and multiplicity in chemically induced murine lung cancer models. We hypothesized that pulmonary prostacyclin synthase overexpression would prevent lung carcinogenesis in tobacco-smoke exposed mice. Murine exposure to tobacco smoke is an established model of inducing pulmonary adenocarcinomas and allows for the testing of potential chemopreventive strategies. Transgenic FVB/N mice with lung-specific prostacyclin synthase overexpression were exposed to mainstream cigarette smoke for 22 weeks and then held unexposed for an additional 20 weeks. All of the exposed animals developed bronchiolitis analogous to the respiratory bronchiolitis seen in human smokers. The transgenic mice, when compared with smoke-exposed transgene negative littermates, had significant decreases in tumor incidence and multiplicity. Significantly fewer transgenics (6 of 15; 40%) developed tumors compared with the tumor incidence in wild-type littermates (16 of 19; 84%; Fisher's exact test, P = 0.012). Tumor multiplicity was also significantly decreased in the transgenic animals (tg+ = 0.4 +/- 0.5 versus wild-type = 1.2 +/- 0.86 tumors/mouse; P < 0.001). Targeted prostaglandin levels at the time of sacrifice revealed significantly elevated prostaglandin I2 levels in the transgenic animals, coupled with significantly decreased prostaglandin E2 levels. Gene expression analysis of isolated type II pneumocytes suggests potential explanations for the observed chemoprevention, with Western blot analysis confirming decreased expression of cytochrome p450 2e1. These studies extend our previous studies and demonstrate that manipulation of prostaglandin production distal to cyclooxygenase significantly reduces lung carcinogenesis in a tobacco smoke exposure model, and gene expression studies show critical alterations in antioxidation, immune response, and cytokine pathways.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15313935     DOI: 10.1158/0008-5472.CAN-04-1070

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

1.  Oral iloprost improves endobronchial dysplasia in former smokers.

Authors:  Robert L Keith; Patrick J Blatchford; John Kittelson; John D Minna; Karen Kelly; Pierre P Massion; Wilbur A Franklin; Jenny Mao; David O Wilson; Daniel T Merrick; Fred R Hirsch; Timothy C Kennedy; Paul A Bunn; Mark W Geraci; York E Miller
Journal:  Cancer Prev Res (Phila)       Date:  2011-06

2.  Chemoprevention of murine lung cancer by gefitinib in combination with prostacyclin synthase overexpression.

Authors:  Robert L Keith; Vijaya Karoor; Anthony B Mozer; Tyler M Hudish; Mysan Le; York E Miller
Journal:  Lung Cancer       Date:  2010-01-29       Impact factor: 5.705

Review 3.  Cyclooxygenases and lipoxygenases in cancer.

Authors:  Claus Schneider; Ambra Pozzi
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

4.  Prostacyclin prevents pulmonary endothelial cell apoptosis induced by cigarette smoke.

Authors:  S Patrick Nana-Sinkam; Jong Deog Lee; Sylk Sotto-Santiago; Robert S Stearman; Robert L Keith; Qamrul Choudhury; Carlyne Cool; Jane Parr; Mark D Moore; Todd M Bull; Norbert F Voelkel; Mark W Geraci
Journal:  Am J Respir Crit Care Med       Date:  2007-01-25       Impact factor: 21.405

Review 5.  Impact of smoking status on the biological behavior of lung cancer.

Authors:  Ichiro Yoshino; Yoshihiko Maehara
Journal:  Surg Today       Date:  2007-08-27       Impact factor: 2.549

Review 6.  Dissecting the role of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in colon, breast, and lung carcinogenesis.

Authors:  Jeffrey M Peters; Jennifer E Foreman; Frank J Gonzalez
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

7.  Regulation of cytokine-induced prostanoid and nitric oxide synthesis by extracellular signal&#x2013;regulated kinase 1/2 in lung epithelial cells.

Authors:  Pamela L Rice; Bradley S Barrett; Jason M Fritz; Mary C Srebernak; Lori R Kisley; Alvin M Malkinson; Lori D Dwyer-Nield
Journal:  Exp Lung Res       Date:  2010-11       Impact factor: 2.459

8.  Targeted overexpression of prostacyclin synthase inhibits lung tumor progression by recruiting CD4+ T lymphocytes in tumors that express MHC class II.

Authors:  Howard Y Li; Maria McSharry; Deandra Walker; Amber Johnson; Jeff Kwak; Bonnie Bullock; Alexander Neuwelt; Joanna M Poczobutt; Trisha R Sippel; Robert L Keith; Mary C M Weiser-Evans; Eric Clambey; Raphael A Nemenoff
Journal:  Oncoimmunology       Date:  2018-02-13       Impact factor: 8.110

9.  Effect of ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) in human lung cancer cell lines.

Authors:  Pengfei He; Michael G Borland; Bokai Zhu; Arun K Sharma; Shantu Amin; Karam El-Bayoumy; Frank J Gonzalez; Jeffrey M Peters
Journal:  Toxicology       Date:  2008-10-02       Impact factor: 4.221

10.  Association of CYP8A1 (Prostacyclin I2 synthase) polymorphism rs5602 with breast cancer in Mexican woman.

Authors:  Eduardo Beltran-Sarmiento; Esaú Floriano-Sánchez; Cindy Bandala; Eleazar Lara-Padilla; Noemí Cárdenas-Rodríguez
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.